IMPACT OF RISK FACTORS ON THE DEVELOPMENT OF RECURRENT CARDIOVASCULAR EVENTS IN PATIENTS WITH MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION DURING THREE YEARS OF FOLLOW-UP
Abstract
Introduction. Patients following myocardial infarction (MI) have a high risk of developing recurrent MI as well as progression of other cardiovascular diseases. Most studies examining outcomes in patients with MI have focused on the acute phase after the index event. In addition, the available scales for predicting early and long-term outcomes of patients with acute coronary syndrome practically do not take into account the phenomenon of comorbidity. The aim of the study — to identify risk factors influencing the development of recurrent cardiovascular events (CVE) during three years of follow-up in patients with acute ST-segment elevation myocardial infarction (STEMI). Materials and methods. Our study included 256 patients diagnosed with STEMI who underwent thrombolytic therapy followed by stenting of the infarct-related artery. The group included 180 men (70%) and 76 women (30%), the mean age of whom was 63.7±0.6 years. During follow-up of the patients for three years after the index event, the results of echocardiogram and lipidogram were evaluated, and recurrent cardiovascular events were analyzed. Research results. Patients were divided into two groups: Group 1 — 177 patients with CVE (69%), Group 2 — 79 patients without CVE (31%). It was revealed that acute kidney injury was diagnosed more often in group 1 than in group 2 — 22 (12.4%) and 1 (1.3%) (p=0.008). The manifestation of acute heart failure at Killip II level in the index hospitalization was 45 (25.4%) patients in the group with CVE and 10 (12.7%) in the group without CVE (p=0.037). The Charlson comorbidity index in group 1 patients was statistically significantly higher than in group 2 patients and was 4.5±0.15 and 3.3±0.15 points (p <0.001). Type 2 diabetes mellitus was statistically significantly more frequent in the group of patients with CVE than without (41 (23.2%) cases to 7 (8.9%) cases p=0.017). Atrial fibrillation was more frequent in 32 (18.1%) patients in group 1 and 3 (3.8%) patients in group 2, which was statistically significant (p=0.004). In group 1, 14 (7.9%) patients had previously suffered an acute cerebral circulation disorder (p=0.023). Group 1 patients were more often obese than group 2 — 75 (42.4%) and 19 (24.1%) (p=0.005). Conclusions. Thus, as a result of the study it was shown that recurrent CVE within 3 years of follow-up are more frequent in patients with obesity, Charlson comorbidity index of 4 and more points, who have a history of acute cerebral circulatory failure, atrial fibrillation, diabetes mellitus and chronic heart failure, as well as those who have suffered in the early postinfarction period such complications as: acute kidney injury, acute heart failure at Killip II level and above.
References
Российское кардиологическое общество (РКО). Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4103. DOI: 10.15829/29/1560-4071-2020-4103.
Byrne R.A., Rossello X., Coughlan J.J. et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826. DOI: 10.1093/eurheartj/ehad191.
Бойцов С.А., Шахнович Р.М., Эрлих А.Д. и др. Регистр острого инфаркта миокарда. РЕГИОН-ИМ — Российский регистр острого инфаркта миокарда. Кардиология. 2021;61(6):4151. DOI: 10.18087/cardio.2021.6.n1595.
Эрлих А.Д. Как за последние несколько лет изменилось лечение пациентов с острым коронарным синдромом с подъемом сегмента ST в клинической практике (данные серии российских регистров «РЕКОРД»). Кардиология. 2018;58(7):23–31. DOI: 10.18087/cardio.2018.7.10140.
Миленькина С.Г., Белогуров А.А., Дельвер Е.П., Староверов И.И. Фармакоинвазивный подход к лечению острого инфаркта миокарда с подъемом сегмента ST. Кардиология. 2020;60(1):62–69. DOI: 10.18087/cardio.2020.1.n699.
Xue Y., Shen J., Hong W. et al. Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles. Lipids Health Dis. 2021;20:48. DOI: 10.1186/s12944-021-01475-z.
Johansson S., Rosengren A., Young K., Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord. 2017;17(1):53. DOI: 10.1186/s12872-017-0482-9.
Rapsomaniki E., Thuresson M., Yang E. et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. Eur Heart J Qual Care Clin Outcomes. 2016;2(3):172–183. DOI: 10.1093/ehjqcco/qcw004.
Johansson S., Rosengren A., Young K., Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord. 2017;17(1):53. DOI: 10.1186/s12872-017-0482-9.
Li S., Peng Y., Wang X. et al. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019;42(3):391–399. DOI: 10.1002/clc.23160.
Ulvenstam A., Graipe A., Irewall A.L. et al. Incidence and predictors of cardiovascular outcomes after acute coronary syndrome in a population-based cohort study. Sci Rep. 2023;13(1):3447. DOI: 10.1038/s41598-023-30597-w.
Burke L.A., Rosenfeld A.G., Daya M.R. et al. Impact of comorbidities by age on symptom presentation for suspected acute coronary syndromes in the emergency department. Eur J Cardiovasc Nurs. 2017;16(6):511–521. DOI: 10.1177/1474515117693891.
Zhang F., Bharadwaj A., Mohamed M.O. et al. Impact of Charlson Co-Morbidity Index Score on Management and Outcomes After Acute Coronary Syndrome. Am J Cardiol. 2020;130:15–23. DOI: 10.1016/j.amjcard.2020.06.022.
Зыков М.В., Дьяченко Н.В., Велиева Р.М. и др. Возможности совместного использования шкалы GRACE и различных индексов коморбидности для повышения эффективности оценки риска госпитальной летальности у больных с острым коронарным синдромом. Терапевтический архив. 2022;94(7):816–821. DOI: 10.26442/00403660.2022.07.201742.
Esdaile H., Hill N., Mayet J., Oliver N. Glycaemic control in people with diabetes following acute myocardial infarction. Diabetes Res Clin Pract. 2023;199:110644. DOI: 10.1016/j.diabres.2023.110644.
Dillinger J.G., Achkouty G., Albert F. et al. FAST-MI investigators. Deleterious synergistic effects of acute heart failure and diabetes mellitus in patients with acute coronary syndrome: Data from the FAST-MI Registries. Arch Cardiovasc Dis. 2022;115(5):264–275. DOI: 10.1016/j.acvd.2022.02.004.
Andersson N.W., Corn G., Dohlmann T.L. et al. LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals. J Am Coll Cardiol. 2023;82(14):1381–1391. DOI: 10.1016/j.jacc.2023.07.027.
Esdaile H., Hill N., Mayet J. et al. Glycaemic control in people with diabetes following acute myocardial infarction. Diabetes Res Clin Pract. 2023;199:110644. DOI: 10.1016/j.diabres.2023.110644.
De Luca G., Verdoia M., Savonitto S. et al. Elderly ACS 2 Investigators. Impact of diabetes on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: insights from the ELDERLY ACS 2 trial. J Cardiovasc Med (Hagerstown). 2020;21(6):453–459. DOI: 10.2459/JCM.0000000000000978.
Fukuoka S., Kurita T., Dohi K. et al. Ito M. Untangling the obesity paradox in patients with acute myocardial infarction after primary percutaneous coronary intervention (detail analysis by age). Int. J. Cardiol. 2019;289:12–18. DOI: 10.1016/j.ijcard.2019.01.011.
De Paola L., Mehta A., Pana T.A. et al. Body Mass Index and Mortality, Recurrence and Readmission after Myocardial Infarction: Systematic Review and Meta-Analysis. J Clin Med. 2022;11(9):2581. DOI: 10.3390/jcm11092581.
Jenča D., Melenovský V., Stehlik J. et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021;8(1):222–237. DOI: 10.1002/ehf2.13144.